Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2024; 14(1): 125-131


Disruption of hyphal development in Candida albicans ATCC 10231 by bioactive compound from Pseudomonas azotoformans UICC B-91

Yonita Aprilia Putri, Rina Hidayati Pratiwi, Wibowo Mangunwardoyo.




Abstract

Candidiasis and other fungal infections are becoming more frequent. The search for appropriate antibiotics for fungal infections is still ongoing. Pseudomonas azotoformans University of Indonesia Culture Collection (UICC) B-91 has potential as an anticandidal. The purpose of this study was to determine the mechanism of inhibition of the metabolite of P. azotoformans UICC B-91 from the medium against morphologically pathogenic fungi. The results showed metabolite compound P. azotoformans UICC B-91 at a concentration of 100 and 80 mg/ml had strong inhibitory power, and 60 mg/ml had moderate inhibition. Determination of the minimum inhibitory concentration value of the medium solution of P. azotoformans UICC B-91 against Candida albicans American Type Culture Collection (ATCC) 10231 was at a concentration of 7.50 mg/ml. Microscopic observation of C. albicans ATCC 10231 after the addition of P. azotoformans UICC B-91 medium under the light microscope showed inhibition of the transition from yeast to hyphae. Microscopic observation of C. albicans ATCC 10231 after the addition of P. azotoformans UICC B-91 medium under scanning electron microscope showed changes in the yeast cell surface become uneven. The mechanism inhibition of metabolites from P. azotoformans UICC B-91 medium against C. albicans ATCC 10231 is through diffusion that disrupts cell membrane function or inhibits transition from yeast to hyphal form.

Key words: anticandidal; C. albicans ATCC 10231; inhibition; mechanism; P. azotoformans UICC B-91






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.